Filing Flows › Pacira BioSciences (PCRX) › Recalls, complaints & regulation
Pacira BioSciences (PCRX): recalls and clinical trials
Pacira BioSciences (PCRX) beyond its filings: 0 recalls in the last 12 months (2 in five years, 0 Class I); 6 active clinical trials.
Latest recalls
- 2024-07-03 · FDA drug · Zilretta (triamcinolone acetonide extended-release injectable suspension), 32 mg per vial, Rx only, Manufactured for: Pacira Pharmaceuticals Inc., San Diego, CA
- 2024-06-19 · FDA drug · Drug Vial Label: Zilretta¿ (triamcinolone acetonide extended-release injectable suspension), 32 mg per vial, Rx only, Manufactured for: Pacira Pharmaceuticals I
Pacira BioSciences' latest quarter
Pacira BioSciences, Q3 2026: revenue $177M (-2% year over year), operating margin 12.6%, net earnings $28.5M, operating cash flow $50.1M. The chart follows the revenue to costs, profit and cash.
Questions
Has Pacira BioSciences had any recalls?
2 recalls on file over five years from the FDA, CPSC and NHTSA; 0 in the last 12 months.
How many clinical trials does Pacira BioSciences have?
6 active studies on ClinicalTrials.gov, 1 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.